pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,006 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1563Endpoints1223BioSpace564Fierce Biotech560BioPharma Dive466raps192onclive165fda recalls
therapy area
allOncology10396Rare Disease2753Immunology2455Cardiology2283Hematology1885Pulmonology1872Vaccines
  • Americans show higher trust in science than most countries, survey finds
    A new Wellcome Global Monitor survey of people in 140 countries found that 52% of Americans say they have a lot of trust in science, compared with just 26% globally. Only 40% of Americans reported…
    STAT · 10d agoNeutral↗ source
  • Endpoints Weekly releases 2026 Women in Biopharma list of 20 honorees after reviewing 200 nominations
    Endpoints Weekly announced its annual Women in Biopharma 2026 project, highlighting leading women in the industry. The editorial team examined close to 200 nominations to select a shortlist. The…
    Endpoints · 11d agoPositive↗ source
← prev
page 8 of 121
next →
102
fda medwatch93
globenewswire health73
fda press54
1645
Psychiatry & CNS1107
Ophthalmology863
Endocrinology & Metabolism687
Pain656
Nephrology643
Half-century after IL-2 discovery, its impact on HIV, cancer and blood safety is highlighted
Robert Gallo marks the 50-year anniversary of the 1976 paper that described interleukin-2, one of the first cytokines identified and essential for T-cell growth. He notes that IL-2 enabled the dis…
STAT · 12d agoPositive↗ source
  • FDA flags safety concern after four deaths in schizophrenia drug trial
    The U.S. Food and Drug Administration issued a warning after four participants died while receiving an experimental treatment for schizophrenia in a clinical study. The agency described the observ…
    STAT · 12d agoRegulatoryNegative↗ source
  • Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surge
    Aspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offer…
    Endpoints · 11d agoDealNeutral↗ source
  • Hospitals file second lawsuit to block Trump admin's 340B rebate pilot
    The American Hospital Association (AHA) has filed another lawsuit against the federal government, challenging a new version of the 340B drug discount program proposed by the Trump administration.…
    STAT · 11d agoRegulatoryNegative↗ source
  • Pharma gifts and payments to doctors linked to higher inappropriate prescribing, study finds
    A Cochrane review of dozens of prior studies found that gifts and payments from drug makers to physicians lead to more inappropriate prescribing and a higher total number of prescriptions, which li…
    STAT · 11d agoNegative↗ source
  • RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%
    New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation. The subgroup resp…
    Endpoints · 12d agoNegative readoutNegative↗ source
  • Proposed Census Overhaul Could Undermine Public Health Data, Experts Warn
    Federal officials are proposing three major revisions to the U.S. Census. The plan would drop questions on race, ethnicity and sexual orientation and would count only U.S. citizens, leaving out non…
    STAT · 12d agoRegulatoryNegative↗ source
  • AI startup Chai Discovery inks GSK deal to develop biologics using artificial intelligence
    Chai Discovery, an artificial‑intelligence focused biotech, has signed a collaboration agreement with GlaxoSmithKline to create biologic medicines using its AI platform. The partnership will lever…
    Endpoints · 12d agoDealPositive↗ source
  • Proposed US Census rule changes could distort health data, warns epidemiologist
    Nancy Krieger, a professor of social epidemiology at Harvard T.H. Chan School of Public Health, wrote an opinion piece warning that proposed changes to the U.S. decennial census could have severe p…
    STAT · 12d agoRegulatoryNegative↗ source
  • TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapy
    TRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of…
    Endpoints · 12d agoDealPositive↗ source
  • Humana tops 2027 Medicare Advantage star ratings as insurers face $13 billion in bonus payouts and legal challenges
    The Centers for Medicare & Medicaid Services released the 2027 star ratings for Medicare Advantage plans, with Humana emerging as the top‑scoring insurer. Plans that achieve at least four out of f…
    STAT · 12d agoRegulatoryNeutral↗ source
  • City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debut
    City Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell a…
    Endpoints · 12d agoDealNeutral↗ source
  • FDA issues early alert on Philips Lumify ultrasound system software and connection problems
    The FDA’s Center for Devices and Radiological Health has released an Early Alert about a potential high‑risk issue with Philips Lumify diagnostic ultrasound devices. The problem involves either a s…
    fda medwatch · 12d agoRegulatoryNegative↗ source
  • Biotech executive Steven Quay dropped from consideration for NIAID director role
    Steven Quay, a biotech executive known for promoting the lab‑leak theory, was reportedly in the running to lead the National Institute for Allergy and Infectious Diseases. A source familiar with t…
    STAT · 11d agoNeutral↗ source
  • Curium lists Bexlutry at $63,524 per infusion, roughly 5% cheaper than Novartis' Lutathera
    Curium announced the list price for its radioligand Bexlutry, a generic version of Novartis' Lutathera. The price is set at $63,524 per infusion, which represents about a five percent discount com…
    Endpoints · 11d agoNeutral↗ source
  • Life Biosciences injects experimental cellular reprogramming drug into three glaucoma patients, reports no serious adverse events
    Life Biosciences provided an update on its early‑stage glaucoma study involving its experimental cellular reprogramming therapy. The company said three patients have each received a single intravi…
    STAT · 12d agoPositive readoutPositive↗ source
  • Researcher uses Reddit data to map post-Roe abortion access barriers
    Betsy Pleasants, a postdoctoral researcher at the Center for Women’s Health Research, began studying how the Covid‑19 pandemic affected abortion services while a graduate student at UC Berkeley. W…
    STAT · 12d agoNeutral↗ source
  • Q32 Bio appoints José Trevejo as chief medical officer, coming from Enveda Therapeutics
    STAT+ ran its regular "up and down the ladder" column highlighting recent personnel moves in the pharma sector. The feature invites readers to share hiring, promotion and departure news for broader…
    STAT · 12d agoNeutral↗ source
  • Viking Therapeutics commercial chief exits after nine months; Gilead eyes BeOne executive for China growth
    Viking Therapeutics' chief commercial officer Neil Aubuchon left the company after only nine months in the role, according to Peer Review. His brief tenure has sparked speculation about the compan…
    Endpoints · 12d agoNeutral↗ source
  • Acting HHS General Counsel Bob Foster Departs Agency
    The acting general counsel for the U.S. Department of Health and Human Services, Bob Foster, is no longer employed by the agency. Endpoints News attempted to reach him via his government email and…
    Endpoints · 12d agoRegulatoryNeutral↗ source
  • MAHA movement fades as midterms approach, lacking visibility and funding
    Health secretary Robert F. Kennedy Jr.'s Make America Healthy Again (MAHA) movement entered the political arena promising to rally an unlikely coalition of activists and deliver significant gains f…
    STAT · 12d agoNegative↗ source
  • Roche partners with Chinese biotech Defand Therapeutics to co-develop new medicines
    Roche announced a partnership with Chinese biotech startup Defand Therapeutics aimed at joint discovery of new drug candidates. Unlike the typical licensing deals where companies obtain rights to…
    STAT · 13d agoDealPositive↗ source
  • Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trial
    Argenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…
    STAT · 13d agoNegative readoutNegative↗ source